Table 1.

Clinical variables by study arm.

Poly EPlaceboTotal
(n = 19)(n = 20)(n = 39)P
Age0.87a
N192039
 Mean (SD)62.1 (9.4)61.4 (7.9)61.7 (8.6)
 Median63.062.062.0
 Q1–Q354.0–70.056.5–66.055.0–67.0
 Range(46.0–77.0)(48.0–77.0)(46.0–77.0)
Sex0.58b
 Female6 (31.6%)8 (40.0%)14 (35.9%)
 Male13 (68.4%)12 (60.0%)25 (64.1%)
Race0.41b
 White17 (89.55%)16 (80.0%)33 (84.6%)
 African American2 (10.55%)4 (20.0%)6 (15.4%)
Prior Aspirin (81 mg)0.80b
 No14 (73.7%)14 (70.0%)28 (71.8%)
 Yes5 (26.3%)6 (30.0%)11 (28.2%)
Institution0.89b
 Hines Veterans admin.8 (42.1%)8 (40.0%)16 (41.0%)
 Mayo Clinic11 (57.9%)12 (60.0%)23 (59.0%)
Disease history0.97b
 Advanced adenomas18 (94.7%)19 (95.0%)37 (94.9%)
 Prior colon cancer1 (5.3%)1 (5.0%)2 (5.1%)
  • aWilcoxon rank-sum test.

  • bχ2 test.